Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, d (Q45910955)

From Wikidata

Jump to navigation Jump to search

scientific article published in June 2012

Language	Label	Description	Also known as
English	Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, d	scientific article published in June 2012

Statements

scholarly article

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/22748590

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, d (English)

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/22748590

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Jürgen Rockstroh

2

object named as

Jürgen K Rockstroh

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/22748590

Jean-Michel Molina

4

object named as

Jean-Michel Molina

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/22748590

5

object named as

Joseph Gathe

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/22748590

Javier Szwarcberg

9

object named as

Javier Szwarcberg

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/22748590

GS-236-0103 Study Team

13

object named as

GS-236-0103 Study Team

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/22748590

author name string

Edwin DeJesus

1

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/22748590

Keith Henry

3

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/22748590

Srinivasan Ramanathan

6

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/22748590

Xuelian Wei

7

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/22748590

Kitty Yale

8

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/22748590

Kirsten White

10

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/22748590

Andrew K Cheng

11

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/22748590

Brian P Kearney

12

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/22748590

language of work or name

0 references

publication date

1 June 2012

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/22748590

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/22748590

379

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/22748590

9835

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/22748590

2429-2438

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/22748590

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE st

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors affecting adherence to antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960918-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(12)60918-0

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/22748590

release_ueahx5nsyjbapky7zmnjl5cpo4

1 reference

https://api.fatcat.wiki/v0/release/ueahx5nsyjbapky7zmnjl5cpo4

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/22748590

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45910955&oldid=1844485318"